Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 in Primary Sclerosing Cholangitis
NCT05896137Phase 2Active, not recruiting
- Sponsor
- Cascade Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linafexor in Primary Sclerosing Cholangitis (PSC), sponsored by Cascade Pharmaceuticals. Started Aug 2023; status: active, not recruiting.
02
Drugs
linafexor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT05896137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896137.